MedKoo Cat#: 329641 | Name: Tolperisone HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tolperisone is a centrally acting muscle relaxant. Tolperisone is a centrally acting muscle relaxant that acts at the reticular formation in the brain stem by blocking voltage-gated sodium and calcium channels. Tolperisone is indicated for use in the treatment of pathologically increased tone of the cross-striated muscle caused by neurological diseases (damage of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis) and of spastic paralysis and other encephalopathies manifested with muscular dystonia.

Chemical Structure

Tolperisone HCl
CAS#3644-61-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 329641

Name: Tolperisone HCl

CAS#: 3644-61-9 (HCl)

Chemical Formula: C16H24ClNO

Exact Mass:

Molecular Weight: 281.82

Elemental Analysis: C, 68.19; H, 8.58; Cl, 12.58; N, 4.97; O, 5.68

Price and Availability

Size Price Availability Quantity
2g USD 450.00 2 Weeks
5g USD 750.00 2 Weeks
10g USD 1,250.00 2 Weeks
25g USD 2,450.00 2 Weeks
50g USD 4,950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
728-88-1 (free base) 3644-61-9 (HCl)
Synonym
Tolperisone; Tolperisone HCl; Tolperisone hydrochloride; AV 650; AV-650; AV650; Midocalm; Muscalm; Mydocalm; N-553.
IUPAC/Chemical Name
2-Methyl-3-piperidino-1-p-tolylpropan-1-one hydrochloride
InChi Key
ZBUVYROEHQQAKL-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H23NO.ClH/c1-13-6-8-15(9-7-13)16(18)14(2)12-17-10-4-3-5-11-17;/h6-9,14H,3-5,10-12H2,1-2H3;1H
SMILES Code
O=C(C1=CC=C(C)C=C1)C(C)CN2CCCCC2.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 281.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Agarwal S, Patel T, Shah N, Patel BM. Comparative study of therapeutic response to baclofen vs tolperisone in spasticity. Biomed Pharmacother. 2017 Mar;87:628-635. doi: 10.1016/j.biopha.2017.01.005. Epub 2017 Jan 10. PubMed PMID: 28086137. 2: Martos V, Hofer KE, Rauber-Lüthy C, Schenk-Jaeger KM, Kupferschmidt H, Ceschi A. Acute toxicity profile of tolperisone in overdose: Observational poison centre-based study. Clin Toxicol (Phila). 2015 Jun;53(5):470-6. doi: 10.3109/15563650.2015.1022896. Epub 2015 Mar 14. PubMed PMID: 25772423. 3: Pawlowska M, Bogiel M, Duda J, Sieradzki E. Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers. Eur J Clin Pharmacol. 2015 Jun;71(6):699-705. doi: 10.1007/s00228-015-1856-5. Epub 2015 May 9. PubMed PMID: 25953735. 4: Kocsis P, Gajári D, Deli L, Gőcze KZ, Pozsgay Z, Tihanyi K. Effect of tolperisone on the resting brain and on evoked responses, an phMRI BOLD study. Brain Res Bull. 2013 Oct;99:34-40. doi: 10.1016/j.brainresbull.2013.09.008. Epub 2013 Oct 4. PubMed PMID: 24099980. 5: Choi CI, Park JI, Lee HI, Lee YJ, Jang CG, Bae JW, Lee SY. Determination of tolperisone in human plasma by liquid chromatography/tandem mass spectrometry for clinical application. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Dec 12;911:59-63. doi: 10.1016/j.jchromb.2012.10.027. Epub 2012 Oct 29. PubMed PMID: 23217307. 6: Owada Y, Takahashi M, Iwasa S, Ichiba H, Sadamoto K, Fukushima T. Enantiomeric separation of tolperisone and eperisone by reversed-phase HPLC with cellulose tris(3-chloro-4-methylphenylcarbamate)-coated chiral column. Biomed Chromatogr. 2014 Jan;28(1):102-5. doi: 10.1002/bmc.2892. Epub 2013 Mar 15. PubMed PMID: 23505060. 7: Sporkert F, Brunel C, Augsburger MP, Mangin P. Fatal tolperisone poisoning: autopsy and toxicology findings in three suicide cases. Forensic Sci Int. 2012 Feb 10;215(1-3):101-4. doi: 10.1016/j.forsciint.2011.05.025. Epub 2011 Jun 17. PubMed PMID: 21683537. 8: Prabhoo R, Keny S, Prabhoo T, Singh A, Rana R. A phase IV observational multi-centre, open-label study on efficacy and safety of tolperisone 150 mg in patients with painful muscle spasm associated with degenerative or inflammatory diseases of the musculoskeletal system. J Assoc Physicians India. 2011 Jan;59:33-7. PubMed PMID: 21751662. 9: Miura N, Saito T, Taira T, Yamagiwa T, Morita S, Inokuchi S. Rapid simultaneous determination of eperisone, tolperisone, and tizanidine in human serum by using a MonoSpin® C18 extraction column and liquid chromatography/tandem mass spectrometry. J AOAC Int. 2014 Nov-Dec;97(6):1546-51. PubMed PMID: 25632432. 10: Nageswara Rao R, Satyanarayana Raju S. Enantioselective separation and simultaneous determination of tolperisone and eperisone in rat plasma by LC-MS/MS. Chirality. 2013 Oct;25(10):622-7. doi: 10.1002/chir.22187. Epub 2013 Jul 9. PubMed PMID: 23840024. 11: Lipták J. [Effectiveness and safety of tolperisone in spasticity following cerebral stroke: randomized, double-blind, placebo-controlled trial]. Ideggyogy Sz. 2013 Jul 30;66(7-8):283-4. Hungarian. PubMed PMID: 23971362. 12: Quasthoff S, Möckel C, Zieglgänsberger W, Schreibmayer W. Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects. CNS Neurosci Ther. 2008 Summer;14(2):107-19. doi: 10.1111/j.1527-3458.2008.00044.x. Review. PubMed PMID: 18482024. 13: Glück J, Rymarczyk B, Rogala B. An immediate hypersensitivity reaction caused by tolperisone hydrochloride. J Investig Allergol Clin Immunol. 2011;21(5):411-2. PubMed PMID: 21905508. 14: Bae JW, Kim MJ, Park YS, Myung CS, Jang CG, Lee SY. Considerable interindividual variation in the pharmacokinetics of tolperisone HCl. Int J Clin Pharmacol Ther. 2007 Feb;45(2):110-3. PubMed PMID: 17323790. 15: Zakharov IaIu, Shirokov VA, Dudin DL. [The effect of tolperisone on the functional state of peripheral motoneurons]. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(3):65-8. Russian. PubMed PMID: 23612413. 16: Orgován G, Tihanyi K, Noszál B. NMR analysis, protonation equilibria and decomposition kinetics of tolperisone. J Pharm Biomed Anal. 2009 Dec 5;50(5):718-23. doi: 10.1016/j.jpba.2009.05.036. Epub 2009 Jun 6. PubMed PMID: 19577875. 17: Bae JW, Park YS, Sohn UD, Myung CS, Ryu BK, Jang CG, Lee SY. HPLC determination of tolperisone in human plasma. Arch Pharm Res. 2006 Apr;29(4):339-42. PubMed PMID: 16681042. 18: Stamenova P, Koytchev R, Kuhn K, Hanasen C, Horvath F, Ramm S, Pongratz D. [A randomized, double blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(1):34-42. Russian. PubMed PMID: 16457132. 19: Kocsis P, Farkas S, Fodor L, Bielik N, Thán M, Kolok S, Gere A, Csejtei M, Tarnawa I. Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46. Epub 2005 Aug 26. PubMed PMID: 16126840. 20: Vora A. Tolperisone. J Assoc Physicians India. 2010 Feb;58:127-8. PubMed PMID: 20653161.